New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTDKS, ALKS, CBRL, BCEI, VAR, MDCO, ARIA, ARQLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Citigroup... Alkermes (ALKS) initiated with a Buy at Citigroup... ArQule (ARQL) initiated with a Buy at Citigroup... Bonanza Creek Energy (BCEI) initiated with a Buy at SunTrust... Dick's Sporting (DKS) initiated with a Market Perform at BMO Capital... The Medicines Co. (MDCO) initiated with a Neutral at Citigroup... Varian Medical (VAR) initiated with a Buy at Brean Capital... Cracker Barrel (CBRL) initiated with a Buy at CL King.
News For ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:20 EDTARQLEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 17, 2014
15:27 EDTDKSDick's Sporting November 47 straddle priced for 7.1% move into Q3
Subscribe for More Information
15:16 EDTDKSNotable companies reporting before tomorrow's open
Subscribe for More Information
14:58 EDTDKSDick's Sporting technical comments before earnings
Subscribe for More Information
07:16 EDTALKSMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
November 13, 2014
12:39 EDTDKSDick's Sporting volatility elevated into Q3 and outlook
Subscribe for More Information
11:54 EDTALKSJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
November 11, 2014
10:00 EDTCBRLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:40 EDTBCEIBonanza Creek appoints Richard Carty as CEO
Subscribe for More Information
08:09 EDTARQLArQule announces collaboration with NIH for ARQ 092 development
Subscribe for More Information
07:49 EDTDKSBofA/Merrill retail and consumer analysts hold analyst/industry conference call
Subscribe for More Information
06:37 EDTCBRLCracker Barrel downgraded to Hold from Buy at Miller Tabak
Subscribe for More Information
November 10, 2014
09:20 EDTARQLOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTARQLArQule says Phase 2 tivantinib trial meets primary endpoint
Subscribe for More Information
07:25 EDTBCEIBonanza Creek price target lowered to $53 from $58 at Brean Capital
Brean Capital lowered its price target to on Bonanza Creek to $53 from $58 to reflect the company's lowered midpoint guidance and higher capital expenditures. Brean Capital reiterates its Buy rating on Bonanza Creek shares.
07:19 EDTALKSCredit Suisse to hold a conference
Subscribe for More Information
07:03 EDTARQLArQule sees FY14 EPS (48c)-(52c), consensus (46c)
Subscribe for More Information
07:02 EDTARQLArQule reports Q3 EPS (10c), consensus (13c)
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use